OBJECTIVE: One way in which parity and use of oral contraceptives may protect against ovarian cancer is by preventing inflammation and oxidative stress associated with ovulation. Since the genes superoxide dismutase (SOD2), myeloperoxidase (MPO), and NAD(P)H:quinone oxidoreductase 1 (NQO1) are involved in inflammation and oxidative stress, we investigated whether variants of these genes are associated with risk of ovarian cancer. METHODS: In a hospital-based case-control study, we compared 125 cases and 193 controls with respect to prevalence of (1) the T-->C (val-->ala) substitution at the -9 position in the signal sequence of SOD2; (2) the G-->A substitution at the -463 position in the promoter region of MPO; and (3) the C-->T (pro-->ser) change in exon 6 of NQO1. Genotyping was done using PCR and gel electrophoresis for MPO and NQO1 and using MALDI-TOF mass spectrometry for SOD2. RESULTS: For SOD2, women with the TC (val/ala) or CC (ala/ala) genotypes were at increased risk [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.1-4.0]. Results for MPO and NQO1 were in the hypothesized directions but were not statistically significant. For MPO, there was a small inverse association among women with GA or AA genotypes (OR = 0.72, 95% CI 0.43-1.2). For NQO1, the TT (ser/ser) genotype was associated with somewhat increased risk (OR = 2.3, 95% CI 0.69-7.6). CONCLUSIONS: While these results need to be confirmed in other studies, they point to a possible role for genes involved in oxidative stress in the development of ovarian cancer.
OBJECTIVE: One way in which parity and use of oral contraceptives may protect against ovarian cancer is by preventing inflammation and oxidative stress associated with ovulation. Since the genes superoxide dismutase (SOD2), myeloperoxidase (MPO), and NAD(P)H:quinone oxidoreductase 1 (NQO1) are involved in inflammation and oxidative stress, we investigated whether variants of these genes are associated with risk of ovarian cancer. METHODS: In a hospital-based case-control study, we compared 125 cases and 193 controls with respect to prevalence of (1) the T-->C (val-->ala) substitution at the -9 position in the signal sequence of SOD2; (2) the G-->A substitution at the -463 position in the promoter region of MPO; and (3) the C-->T (pro-->ser) change in exon 6 of NQO1. Genotyping was done using PCR and gel electrophoresis for MPO and NQO1 and using MALDI-TOF mass spectrometry for SOD2. RESULTS: For SOD2, women with the TC (val/ala) or CC (ala/ala) genotypes were at increased risk [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.1-4.0]. Results for MPO and NQO1 were in the hypothesized directions but were not statistically significant. For MPO, there was a small inverse association among women with GA or AA genotypes (OR = 0.72, 95% CI 0.43-1.2). For NQO1, the TT (ser/ser) genotype was associated with somewhat increased risk (OR = 2.3, 95% CI 0.69-7.6). CONCLUSIONS: While these results need to be confirmed in other studies, they point to a possible role for genes involved in oxidative stress in the development of ovarian cancer.
Authors: Ana Luisa Miranda-Vilela; Graciana Souza Lordelo; Arthur Kenji Akimoto; Penha Cristina Zaidan Alves; Luiz Carlos da Silva Pereira; Maria de Nazaré Klautau-Guimarães; Cesar Koppe Grisolia Journal: Genes Nutr Date: 2011-04-11 Impact factor: 5.523
Authors: Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa Journal: J Natl Cancer Inst Date: 2010-06-28 Impact factor: 13.506
Authors: Anatoly Samoylenko; Jubayer Al Hossain; Daniela Mennerich; Sakari Kellokumpu; Jukka Kalervo Hiltunen; Thomas Kietzmann Journal: Antioxid Redox Signal Date: 2013-04-15 Impact factor: 8.401
Authors: Chunyan He; Rulla M Tamimi; Susan E Hankinson; David J Hunter; Jiali Han Journal: Breast Cancer Res Treat Date: 2008-03-14 Impact factor: 4.872
Authors: Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Keith Y Terada; Marc T Goodman Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254
Authors: Preetha Rajaraman; Amy Hutchinson; Nathaniel Rothman; Peter M Black; Howard A Fine; Jay S Loeffler; Robert G Selker; William R Shapiro; Martha S Linet; Peter D Inskip Journal: Neuro Oncol Date: 2008-08-05 Impact factor: 12.300
Authors: Dan Cacsire Castillo-Tong; Dietmar Pils; Georg Heinze; Ioana Braicu; Jalid Sehouli; Alexander Reinthaller; Eva Schuster; Andrea Wolf; Rafal Watrowski; Richard A Maki; Robert Zeillinger; Wanda F Reynolds Journal: Tumour Biol Date: 2013-07-27